Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqGS - Nasdaq Real Time Price USD

Day One Biopharmaceuticals, Inc. (DAWN)

Compare
7.61
-0.32
(-4.04%)
At close: April 1 at 4:00:01 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
131,161
131,161
--
--
--
Cost of Revenue
5,279
5,279
--
--
--
Gross Profit
125,882
125,882
--
--
--
Operating Expense
343,152
343,152
206,064
146,909
72,743
Operating Income
-217,270
-217,270
-206,064
-146,909
-72,743
Net Non Operating Interest Income Expense
--
--
--
4,746
4
Other Income Expense
128,918
128,918
17,147
4,728
-11
Pretax Income
-88,352
-88,352
-188,917
-142,181
-72,754
Tax Provision
7,144
7,144
--
--
--
Net Income Common Stockholders
-95,496
-95,496
-188,917
-142,181
-170,639
Diluted NI Available to Com Stockholders
-95,496
-95,496
-188,917
-142,181
-170,639
Basic EPS
-0.97
-1.02
-2.37
-2.17
-4.62
Diluted EPS
-0.97
-1.02
-2.37
-2.17
-4.62
Basic Average Shares
89,135
93,234.20
79,773
65,466.77
36,960.57
Diluted Average Shares
89,135
93,234.20
79,773
65,466.77
36,960.57
Total Operating Income as Reported
-217,270
-217,270
-206,064
-146,909
-72,743
Total Expenses
348,431
348,431
206,064
146,909
72,743
Net Income from Continuing & Discontinued Operation
-95,496
-95,496
-188,917
-142,181
-70,645
Normalized Income
-111,059.79
-111,059.79
-206,104
-146,927
-70,649
Net Interest Income
--
--
--
4,746
4
EBIT
-217,270
-217,270
-206,064
-146,909
-72,743
EBITDA
-215,241
-215,241
-205,681
-146,378
-72,544
Reconciled Cost of Revenue
5,279
5,279
--
--
--
Reconciled Depreciation
2,029
2,029
383
531
199
Net Income from Continuing Operation Net Minority Interest
-95,496
-95,496
-188,917
-142,181
-70,645
Total Unusual Items Excluding Goodwill
19,701
19,701
17,187
4,746
4
Total Unusual Items
19,701
19,701
17,187
4,746
4
Normalized EBITDA
-234,942
-234,942
-222,868
-151,124
-72,548
Tax Rate for Calcs
0
0
--
--
--
Tax Effect of Unusual Items
4,137.21
4,137.21
--
--
--
12/31/2021 - 5/27/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SWTX SpringWorks Therapeutics, Inc.
41.88
-5.10%
 
PDSB PDS Biotechnology Corporation
1.0800
-9.24%
 
SNDX Syndax Pharmaceuticals, Inc.
12.01
-2.24%
 
RVMD Revolution Medicines, Inc.
33.62
-4.92%
 
IDYA IDEAYA Biosciences, Inc.
14.77
-9.83%
 
TARS Tarsus Pharmaceuticals, Inc.
48.92
-4.77%
 
CYTK Cytokinetics, Incorporated
37.50
-6.69%
 
BCYC Bicycle Therapeutics plc
7.85
-7.54%
 
PHAT Phathom Pharmaceuticals, Inc.
5.12
-18.34%
 
JANX Janux Therapeutics, Inc.
26.81
-0.70%